PRT1419: PRT1419 is a selective inhibitor of MCL1 developed by Prelude Therapeutics (https://preludetx.com) that has demonstrated preclinical efficacy in hematologic malignancies and solid tumors. The gene discussed is MCL1; the disease is hematologic disorder.